

MFS® Blended Research® Small Cap

Equity Fund

(Class R6 Shares) Fourth quarter 2024 investment report

NOT FDIC INSURED MAY LOSE VALUE NOT A DEPOSIT

Before investing, consider the fund's investment objectives, risks, charges, and expenses. For a prospectus, or summary prospectus, containing this and other information, contact MFS or view online at mfs.com. Please read it carefully.

©2025 MFS Fund Distributors, Inc., Member SIPC, 111 Huntington Avenue, Boston, MA 02199.

FOR DEALER AND INSTITUTIONAL USE ONLY. Not to be shown, quoted, or distributed to the public. PRPEQ-BRS-31-Dec-24

Table of Contents



Page
1
2
3
4
5
15
16
18
20
24
28

Performance and attribution results are for the fund or share class depicted and do not reflect the impact of your contributions and withdrawals. Your personal performance results may differ.

Portfolio characteristics are based on equivalent exposure, which measures how a portfolio's value would change due to price changes in an asset held either directly or, in the case of a derivative contract, indirectly. The market value of the holding may differ.

Fund Risks and Investment Objective



The fund may not achieve its objective and/or you could lose money on your investment in the fund.

Stock: Stock markets and investments in individual stocks are volatile and can decline significantly in response to or investor perception of, issuer, market, economic, industry, political, regulatory, geopolitical, environmental, public health, and other conditions.

Small-cap: Investments in small-cap companies can be more volatile than investments in larger companies.


Strategy: There is no assurance that the portfolio's predicted tracking error will equal its target predicted tracking error at any point in time or consistently for any period of time, or that the portfolio's predicted tracking error and actual tracking error will be similar. The portfolio's strategy to target a predicted tracking error of approximately 3% compared to the Index and to blend fundamental and quantitative research may not produce the intended results. In addition, MFS fundamental research is not available for all issuers.

Quantitative Strategy: MFS' investment analysis, development and use of quantitative models, and selection of investments may not produce the intended results and/or can lead to an investment focus that results in underperforming portfolios with similar investment strategies and/or the markets in which the portfolio invests. The proprietary and third party quantitative models used by MFS may not produce the intended results for a variety of reasons, including the factors used, the weight placed on each factor, changing sources of market return, changes from the market factors' historical trends, and technical issues in the development, application, and maintenance of the models (e.g., incomplete or inaccurate data, programming/software issues, coding errors and technology failures). Please see the prospectus for further information on these and other risk considerations.

Investment Objective: Seeks capital appreciation.


Market Overview





Style performance (%) (USD) as of 31-Dec-24

Sector performance (%) (USD) as of 31-Dec-24



Past performance is not a reliable indicator for future results.

Source for benchmark performance SPAR, FactSet Research Systems Inc. All indices represent total return unless otherwise noted.

US equities market review as of 31 December 2024

- The US market, as measured by the S&P 500 Index, finished higher in Q4 2024. While the market ended the quarter with a gain, it gave back some of that return in December. Investors used the last month of the year to lock in some profits from a strong year as well as to recognize the uncertainty in many areas in 2025.
- Economic growth in the United States expanded during Q3 2024, with GDP increasing 3.1%. This was similar to Q2 and showed that the US economy was still performing well. With inflation heading toward the US Federal Reserve's 2% goal, the Fed cut rates two times, each by 25 basis


Source: FactSet. Sector performance based on MSCI sector classification. The analysis of Russell 2000[®] Index constituents are broken out by MSCI defined sectors.

points, during the quarter. However, the Fed also announced that fewer cuts than anticipated were likely in 2025.

• For the guarter, growth outperformed value in the large-, mid- and smallcap spaces. Consumer discretionary, communication services and financials were the best-performing sectors, and materials, health care and real estate were the worst.

Executive Summary





Performance results (%) R6 shares at NAV (USD) as of 31-Dec-24

Benchmark^

Position weights (%) as of 31-Dec-24 Portfolio Benchmark[^] Top overweights ENCOMPASS HEALTH CORP 1.6 _ PRESTIGE CONSUMER HEALTHCARE INC 1.7 0.1 GRAND CANYON EDUCATION INC 1.5 _ Top underweights FTAI AVIATION LTD 0.5 _ SPROUTS FARMERS MARKET INC 0.5 _ INSMED INC _ 0.4

^^ Russell 2000[®] Index

(15-Sep-15)

Portfolio

Performance data shown represent past performance and are no guarantee of future results. Investment return and principal value fluctuate so your shares, when sold, may be worth more or less than the original cost; current performance may be lower or higher than quoted. For most recent month-end performance, please visit mfs.com.

Performance results reflect any applicable expense subsidies and waivers in effect during the periods shown. Without such subsidies and waivers the fund's performance results would be less favorable. All results assume the reinvestment of dividends and capital gains.

Shares are available without a sales charge to eligible investors.

Source for benchmark performance SPAR, FactSet Research Systems Inc.

For periods of less than one-year returns are not annualized.

^ Russell 2000[®] Index



r enormance results (70) No shares at NAV (05D) as of 51-bet-24							
Period	Portfolio	Benchmark [^]	Excess return vs benchmark				
4Q 2024	-0.59	0.33	-0.93				
3Q 2024	6.27	9.27	-3.00				
2Q 2024	-4.24	-3.28	-0.96				
1Q 2024	3.74	5.18	-1.44				
2024	4.95	11.54	-6.59				
2023	18.90	16.93	1.98				
2022	-18.31	-20.44	2.12				
2021	29.16	14.82	14.34				
2020	2.21	19.96	-17.75				
ife (15-Sep-15)	8.73	8.83	-0.10				
year	6.12	7.40	-1.29				
year	0.64	1.24	-0.60				
year	4.95	11.54	-6.59				

Performance results [%] R6 shares at NAV (USD) as of 31-Dec-24

Performance data shown represent past performance and are no guarantee of future results. Investment return and principal value fluctuate so your shares, when sold, may be worth more or less than the original cost; current performance may be lower or higher than quoted. For most recent month-end performance, please visit mfs.com. Performance results reflect any applicable expense subsidies and waivers in effect during the periods shown. Without such subsidies and waivers the fund's performance results would be less favorable. All results assume the reinvestment of dividends and capital gains.

Shares are available without a sales charge to eligible investors.

Source for benchmark performance SPAR, FactSet Research Systems Inc.


For periods of less than one-year returns are not annualized.

^ Russell 2000[®] Index

Investment Process Performance Drivers



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024



Please note that the figures provided above do not total to the active return.

Active return represents the difference between the portfolio return and the benchmark return over the time period examined. Active return not explained by the total effect of the intersection holdings will be captured by the total effect of non-intersection stocks, and is not shown in this summary.~ Intersectionholdings represent stocks that are considered attractive from both fundamental and quantitative research sources.

Active return not captured by the allocation effects associated with each respective factor within Research Inputs and Quantitative Themes will be captured by selection and interaction effects, which are not included in this summary.

Results are calculated based on a Brinson-Fachler based performance attribution analysis, grouped by a single factor, generated utilizing Factset's Portfolio Analysis platform. Attributions attempt to decompose a portfolio's performance relative to a benchmark by grouping securities into discrete buckets and attributing returns across these groupings along three dimensions: the allocation effect, the selection effect, and the interaction effect. The groupings are based on beginning of period ratings and scores, rebalanced monthly. The groupings do not reflect intra-month ratings and score changes and may not align with the actual trade rebalance dates of the portfolio. Results are based upon daily holdings to generate individual security returns and do not include expenses, intra-day trading, or intra-day pricing impacts. As a result, portfolio and benchmark returns generated through attribution analysis will likely differ from actual returns.

Total effect represents the combination of allocation, selection and interaction effects associated with Intersection Holdings. MFS defines intersection holdings as stocks with a Fundamental buy rating that are scored within the most attractive tercile of MFS' overall Quantitative Model score. MFS Fundamental analysts rate stocks with a buy, hold or sell rating. Not all stocks are fundamentally rated and stocks without a fundamental rating are treated the same as hold rated stocks. MFS' proprietary quantitative stock selection model ranks stocks on a scale of 1-100.

Allocation Effect represents the contribution to relative performance associated with an overweight or underweight to a particular grouping of stocks from a single Brinson Fachler attribution (i.e., the contribution associated with investments in top quintile stocks based on valuation). It is calculated daily as the difference between the stock portfolio weight of a grouping and benchmark weight for that same grouping, multiplied by the difference between the benchmark's stock grouping return and overall benchmark return. The daily allocation effects are geometrically linked over the reporting period.

Performance Drivers - Fundamental Research



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024

	Portfolio	Benchmark	Variation	Attribution Analysis		
Fundamental Research	Total Return	Total Return	Average Weight Diff	Allocation Effect	Selection Effect ¹	Total Effect
Fundamental Buy	1.0	-0.1	48.1	-0.1	0.6	0.4
Fundamental Hold/unrated	-2.7	0.4	-45.9	-0.0	-1.4	-1.4
Fundamental Sell	-	-1.3	-2.9	0.0	-	0.0
Cash	1.1	-	0.6	0.1	-	0.1
Total	-0.5	0.3	-	-0.0	-0.8	-0.8

¹ Stock selection includes interaction effect. Interaction effect is the portion of the portfolio's relative performance attributable to combining allocation decisions with stock selection decisions. This effect measures the relative strength of the manager's convictions. The interaction effect is the weight differential times the return differential. Stocks without a rating are treated the same as hold rated stocks for the purpose of creating a blended research score. Stocks without a fundamental rating accounted for 36.6% of the portfolio and 78.3% of the index.

Attribution results are generated by the FactSet application utilizing a methodology that is widely accepted in the investment industry. Results are based upon daily holdings using a buy-and-hold methodology to generate individual security returns and do not include fees or expenses. As such, attribution results are essentially estimates and do not aggregate to the total return of the portfolio, which can be found elsewhere in this presentation. Recent geopolitical events may have impacted or disrupted the pricing of specific securities including the use of fair valuation approaches. Fair valuation practices across pricing sources – index providers, pricing vendors, MFS - may not align due to security specific considerations or timing of fair valuation parameters. For instance, decisions to use stale prices vs fair value or on the level of haircut when fair valuing securities are typical sources of discrepancy between pricing sources observed during the events. As these securities are bought or sold, the portion of the security's return attributed to the difference between fair value price and trade price will not be recognized in attribution results. These factors may further compound differences between attribution results and actual performance. To obtain the contribution calculation methodology and a complete list of every holding's contribution to the overall portfolio's performance during the measurement period, please email DLAttributionGrp@MFS.com.

Performance Drivers - Quantitative Research



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024

	Portfolio	Benchmark	Variation	Attribution Analysis		
Quantitative Research	Total Return	Total Return	Average Weight Diff	Allocation Effect	Selection Effect ¹	Total Effect
Quant Q1 - Best	0.0	-0.4	27.9	-0.2	0.2	0.0
Quant Q2	-2.6	-0.8	6.2	-0.0	-0.6	-0.6
Quant Q3	1.5	-1.0	-7.8	0.2	0.5	0.7
Quant Q4	-4.6	-1.6	-12.5	0.2	-0.1	0.1
Quant Q5 - Worst	-3.4	8.0	-14.3	-1.1	-0.1	-1.2
Cash	1.1	-	0.6	0.1	-	0.1
Unassigned	-10.3	-26.9	-0.1	0.1	-0.0	0.0
Total	-0.5	0.3	-	-0.7	-0.1	-0.8

Performance Drivers - Valuation



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024

	Portfolio	Benchmark	Variation	Attribution Analysis		
Valuation	Total Return	Total Return	Average Weight Diff	Allocation Effect	Selection Effect ¹	Total Effect
Valuation Q1 - Best	0.2	-0.4	26.6	-0.3	0.3	0.0
Valuation Q2	2.0	1.3	6.1	0.1	0.1	0.2
Valuation Q3	-6.2	-1.3	-4.3	0.0	-0.9	-0.9
Valuation Q4	1.5	-1.5	-14.1	0.3	0.5	0.8
Valuation Q5 - Worst	-2.3	5.3	-14.7	-0.7	-0.3	-1.1
Cash	1.1	-	0.6	0.1	-	0.1
Unassigned	-10.3	-26.9	-0.1	0.1	-0.0	0.0
Total	-0.5	0.3	-	-0.5	-0.4	-0.8

Performance Drivers - Earnings Momentum



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024

	Portfolio	Benchmark	Variation	Attribution Analysis		
Earnings Momentum	Total Return	Total Return	Average Weight Diff	Allocation Effect	Selection Effect ¹	Total Effect
Earnings Momentum Q1 - Best	-0.2	3.1	-5.3	-0.1	-0.6	-0.8
Earnings Momentum Q2	0.6	-0.7	2.1	0.0	0.3	0.3
Earnings Momentum Q3	3.4	0.6	3.1	-0.0	0.7	0.7
Earnings Momentum Q4	-5.5	-3.1	2.6	-0.1	-0.5	-0.6
Earnings Momentum Q5 - Worst	-3.7	1.3	-3.0	-0.0	-0.5	-0.6
Cash	1.1	-	0.6	0.1	-	0.1
Unassigned	-10.3	-26.9	-0.1	0.1	-0.0	0.0
Total	-0.5	0.3	-	-0.1	-0.7	-0.8

Performance Drivers - Quality



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024

	Portfolio	Benchmark	Variation	Attribution Analysis		
Quality	Total Return	Total Return	Average Weight Diff	Allocation Effect	Selection Effect ¹	Total Effect
Quality Q1 - Best	-0.2	-0.7	9.7	-0.1	0.1	0.0
Quality Q2	-0.7	-0.6	4.2	-0.0	-0.0	-0.1
Quality Q3	-2.7	-0.0	2.2	0.0	-0.8	-0.8
Quality Q4	1.4	-2.3	-5.5	0.2	0.5	0.7
Quality Q5 - Worst	5.5	6.9	-11.2	-0.7	-0.1	-0.8
Cash	1.1	-	0.6	0.1	-	0.1
Unassigned	-10.3	-26.9	-0.1	0.1	-0.0	0.0
Total	-0.5	0.3	-	-0.5	-0.3	-0.8

Performance Drivers - Price Momentum



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024

	Portfolio	Benchmark	Variation	Attribution Analysis		
Price Momentum	Total Return	Total Return	Average Weight Diff	Allocation Effect	Selection Effect ¹	Total Effect
Price Momentum Q1 - Best	-1.9	-1.1	-4.0	0.1	-0.2	-0.2
Price Momentum Q2	-3.1	-0.5	0.8	0.0	-0.6	-0.6
Price Momentum Q3	4.1	0.9	3.4	0.0	0.8	0.9
Price Momentum Q4	1.1	0.3	1.9	-0.0	0.1	0.1
Price Momentum Q5 - Worst	-6.0	3.6	-2.6	-0.1	-1.0	-1.1
Cash	1.1	-	0.6	0.1	-	0.1
Unassigned	-10.3	-26.9	-0.1	0.1	-0.0	0.0
Total	-0.5	0.3	-	0.1	-0.9	-0.8

Performance Drivers - Sentiment



Relative to Russell 2000[®] Index (USD) - fourth quarter 2024

	Portfolio	Benchmark	Variation	Attribution Analysis		
Sentiment	Total Return	Total Return	Average Weight Diff	Allocation Effect	Selection Effect ¹	Total Effect
Sentiment Q1 - Best	-1.4	-2.7	12.2	-0.4	0.4	-0.0
Sentiment Q2	-4.4	-2.2	1.8	-0.0	-0.7	-0.8
Sentiment Q3	3.7	3.3	-2.4	-0.1	0.1	0.0
Sentiment Q4	5.9	2.3	-0.8	0.0	0.5	0.5
Sentiment Q5 - Worst	-2.2	3.1	-11.3	-0.4	-0.3	-0.7
Cash	1.1	-	0.6	0.1	-	0.1
Unassigned	-10.3	-26.9	-0.1	0.1	-0.0	0.0
Total	-0.5	0.3	-	-0.7	-0.1	-0.8

Performance Drivers - Sectors



Relative to Rus fourth quarter	ssell 2000® Index (USD) - 2024	Average relative weighting (%)	Portfolio returns (%)	Benchmark returns (%)	Sector allocation ¹ (%	Stock + selection ² (%)	Relative contribution (%)
Contributors	Consumer Discretionary	1.4	11.4	-1.7	-0.0	1.4	1.4
	Health Care	1.0	-4.6	-7.6	-0.1	0.5	0.5
	Financials	1.2	4.7	3.5	0.0	0.2	0.3
	Utilities	-1.2	7.1	-4.6	0.0	0.2	0.2
	Cash	0.6	1.1	_	0.1	_	0.1
	Consumer Staples	-1.3	12.7	5.6	-0.1	0.1	0.1
Detractors	Information Technology	-0.3	0.2	9.7	-0.0	-1.1	-1.1
	Industrials	-1.4	-1.1	4.1	-0.0	-0.8	-0.9
	Energy	0.3	-13.1	-2.7	-0.0	-0.6	-0.7
	Materials	0.3	-14.7	-4.7	-0.0	-0.5	-0.5
	Real Estate	-0.6	-7.5	-6.0	0.0	-0.1	-0.1
	Communication Services	0.0	-0.5	0.7	-0.0	-0.0	-0.0
Total			-0.5	0.3	-0.1	-0.7	-0.8

1 Sector allocation is calculated based upon each security's price in local currency.

² Stock selection is calculated based upon each security's price in local currency and included interaction effect. Interaction effect is the portfolio's relative performance attributable to combining allocation decisions with stock selection decisions. This effect measures the relative strength of the manager's convictions. The interaction effect is the weight differential times the return differential.

Attribution results are generated by the FactSet application utilizing a methodology that is widely accepted in the investment industry. Results are based upon daily holdings using a buy-and-hold methodology to generate individual security returns and do not include fees or expenses. As such, attribution results are essentially estimates and do not aggregate to the total return of the portfolio, which can be found elsewhere in this presentation. Recent geopolitical events may have impacted or disrupted the pricing of specific securities including the use of fair valuation approaches. Fair valuation practices across pricing sources – index providers, pricing vendors, MFS - may not align due to security specific considerations or timing of fair valuation parameters. For instance, decisions to use stale prices vs fair value or on the level of haircut when fair valuing securities are typical sources of discrepancy between pricing sources observed during the events. As these securities are bought or sold, the portion of the security's return attributed to the difference between fair value price and trade price will not be recognized in attribution results. These factors may further compound differences between attribution results and actual performance. To obtain the contribution calculation methodology and a complete list of every holding's contribution to the overall portfolio's performance during the measurement period, please email DLAttributionGrp@MFS.com.

The Global Industry Classification Standard (GICS[®]) was developed by and/or is the exclusive property of MSCI, Inc. and S&P Global Market Intelligence Inc. ("S&P Global Market Intelligence"). GICS is a service mark of MSCI and S&P Global Market Intelligence and has been licensed for use by MFS. MFS has applied its own internal sector/industry classification methodology for equity securities and non-equity securities that are unclassified by GICS.

Performance Drivers - Stocks



		Average W	/eighting (%)	Retu	r ns (%)	
Relative to Russell 2000 $^{ m e}$ Index (USD) - fourth quarter 2024		Portfolio	Benchmark	Portfolio ¹	Benchmark	Relative contribution(%)
Contributors	Newell Brands Inc	1.6	_	30.6	_	0.4
	Carvana Co	1.2	_	28.1	—	0.4
	Taskus Inc	1.1	_	31.1	_	0.3
	Slm Corp	1.4	_	21.2	—	0.3
	Grand Canyon Education Inc	1.5	_	15.5	_	0.2
Detractors	Axcelis Technologies Inc	0.9	0.1	-33.4	-33.4	-0.3
	Organon & Co	1.1	—	-20.6	—	-0.3
	lonq Inc	_	0.2	—	377.9	-0.2
	Tronox Holdings Plc	0.7	0.1	-30.4	-30.4	-0.2
	Builders Firstsource Inc (Eq)	0.7	_	-26.3	_	-0.2

¹ Represents performance for the time period stock was held in portfolio.

Attribution results are generated by the FactSet application utilizing a methodology that is widely accepted in the investment industry. Results are based upon daily holdings using a buy-and-hold methodology to generate individual security returns and do not include fees or expenses. As such, attribution results are essentially estimates and do not aggregate to the total return of the portfolio, which can be found elsewhere in this presentation. Recent geopolitical events may have impacted or disrupted the pricing of specific securities including the use of fair valuation approaches. Fair valuation practices across pricing sources – index providers, pricing vendors, MFS - may not align due to security specific considerations or timing of fair valuation parameters. For instance, decisions to use stale prices vs fair value or on the level of haircut when fair valuing securities are typical sources of discrepancy between pricing sources observed during the events. As these securities are bought or sold, the portion of the security's return attributed to the difference between fair value price and trade price will not be recognized in attribution results. These factors may further compound differences between attribution results and actual performance. To obtain the contribution calculation methodology and a complete list of every holding's contribution to the overall portfolio's performance during the measurement period, please email DLAttributionGrp@MFS.com.

Significant Transactions



From 01-0ct-24	to 31-Dec-24	Transaction type	Trade (%)	Ending weight (%)
Purchases	TEXAS CAPITAL BANCSHARES INC	New position	1.2	1.1
	MOHAWK INDS INC EQ	New position	0.8	0.8
	WNS HOLDINGS LTD	New position	0.7	0.7
	BATH & BODY WORKS INC New position	New position	0.6	0.7
	WOLVERINE WORLD WIDE INC	New position	0.6	0.6
Sales	CARVANA CO	Eliminate position	-1.7	_
	SKECHERS USA INC	Eliminate position	-1.3	_
	TANGER INC	Eliminate position	-1.0	_
	VERADIGM INC	Eliminate position	-1.0	_
	ENVISTA HOLDINGS CORP	Eliminate position	-0.7	_

Sector Weights



As of 31-Dec-24	Portfolio (%)	Benchmark^ (%)	Underweight/overweight (%)
Consumer Discretionary	11.2	9.7	1.5
Financials	19.7	18.5	1.2
Materials	4.9	4.3	0.6
Communication Services	3.2	2.7	0.5
Health Care	16.6	16.4	0.2
Energy	5.2	5.1	0.1
Information Technology	13.6	13.8	-0.2
Real Estate	5.2	6.1	-0.9
Consumer Staples	1.6	2.8	-1.2
Utilities	1.5	2.7	-1.2
Industrials	16.1	18.0	-1.9

^ Russell 2000[®] Index

1.1% Cash & cash equivalents

The Global Industry Classification Standard (GICS[®]) was developed by and/or is the exclusive property of MSCI, Inc. and S&P Global Market Intelligence Inc. ("S&P Global Market Intelligence"). GICS is a service mark of MSCI and S&P Global Market Intelligence and has been licensed for use by MFS. MFS has applied its own internal sector/industry classification methodology for equity securities and non-equity securities that are unclassified by GICS.

Top Overweight and Underweight Positions



As of 31-Dec-24		Portfolio (%)	Benchmark^ (%)
Overweight	ENCOMPASS HEALTH CORP	1.6	_
	PRESTIGE CONSUMER HEALTHCARE INC	1.7	0.1
	GRAND CANYON EDUCATION INC	1.5	_
	PIEDMONT OFFICE REALTY TRUST INC	1.5	0.0
	NEWELL BRANDS INC	1.5	_
Underweight	FTAI AVIATION LTD	-	0.5
	SPROUTS FARMERS MARKET INC	_	0.5
	INSMED INC	-	0.4
	VAXCYTE INC	-	0.4
	CREDO TECHNOLOGY GROUP HOLDING LTD	-	0.4

^ Russell 2000[®] Index

Characteristics

As of 31-Dec-24	Portfolio	Benchmark [^]
Fundamentals - weighted average		
Price/earnings (12 months forward ex-negative earnings)	13.4x	16.3x
Price/book	1.8x	1.9x
Price/sales	1.0x	1.4x
Market capitalization		
Market capitalization (USD) ¹	4.3 bn	3.6 bn
Diversification		
Top ten issues	15%	4%
Number of Issues	182	1,966
Turnover		
Trailing 1 year turnover ²	69%	—
Risk profile (current)		
Active share	92%	_

- ¹ Weighted average.
- ² US Turnover Methodology: (Lesser of Purchase or Sales)/Average Month End Market Value

^ Russell 2000[®] Index

No forecasts can be guaranteed.

Top 10 Issuers



Top 10 issuers as of 31-Dec-24	Portfolio (%)	Benchmark^ (%)
PRESTIGE CONSUMER HEALTHCARE INC	1.7	0.1
ENCOMPASS HEALTH CORP	1.6	-
GRAND CANYON EDUCATION INC	1.5	-
PIEDMONT OFFICE REALTY TRUST INC	1.5	0.0
FUNKO INC	1.5	0.0
NEWELL BRANDS INC	1.5	-
ARMSTRONG WORLD INDUSTRIES INC	1.4	-
COLUMBIA BANKING SYSTEM INC	1.4	-
API GROUP CORP	1.4	-
CATHAY GENERAL BANCORP	1.4	0.1
Total	14.8	0.3

^ Russell 2000[®] Index



For the fourth quarter of 2024, the portfolio underperformed the Russell 2000[®] Index.

Detractors

- Quantitative models: sentiment, quality and valuation
- Stock selection within information technology, industrials, energy and materials

Contributors

• Stock selection within consumer discretionary and health care

Market review

The S&P 500 finished the 4th quarter below its all-time high, hit in early December, following another quarter of market-moving events and volatility. In October the market retreated as expectations for future US Federal Reserve rate cuts moderated, bond yields shifted higher and uncertainty about the outcome of the US election spooked markets. The market resumed higher in November and rallied strongly after the decisive results from the US election and from investor optimism about the potential for the extension of the 2017 tax cuts as well as a friendlier regulatory environment. The November rally carried into early December before a back-up in bond yields and hawkish comments by US Federal Reserve Chair Powell resulted in a volatile sell-off to end the year.

Inflation, globally, is well off the 2022 highs, although progress has stalled in many economies, with service prices and wages remaining sticky. Having said that, more than 75% of central banks are cutting rates, but the pace of policy easing has moderated with both the Fed and Bank of England signaling a more gradual approach. The European Central Bank, despite stubbornly high wage growth, communicated policy is still restrictive and will continue to cut its deposit facility rate in response to weak economic activity. Despite stronger-than-expected inflation in Japan, the Bank of Japan held the policy rate steady while indicating it remained on a tightening track. In the emerging markets, weak consumption and lower-than-expected inflation reports are prompting further stimulative policies in China, while in Brazil inflation is running well above target, forcing the Central Bank of Brazil (BCB) to increase the Selic rate by a greater-than-expected 100 basis points in early December.



The outlook for the global economy, considered through the lens of leading indicators such as PMIs, remains bifurcated by geography and sector. The most recent (November) global composite PMI reading continued to signal expansion, with the dispersion between the manufacturing and services sectors persisting, although the strength and momentum in the latter has started to wane. The global manufacturing PMI slid back below 50, into contraction, in December; however, breadth measures were mixed, with the percentage of economies in expansion increasing to 47%, although only 42% of economies reported a positive month-month increase. Flashing a more optimistic tone was the forward-looking new orders versus inventories ratio, which is now above zero, with 67% of economies reporting new orders exceeding inventories. Regionally, manufacturing is strongest in emerging market economies such as India, Greece, the Philippines and Taiwan, while major developed economies such as the eurozone and Pacific ex-Japan remain deep in contraction. The manufacturing PMIs for the US and Japan remain slightly below 50, but there were signs stabilization/improvement in the December reports.

Q3 earnings were generally better than expectations; however, EPS growth rates were sequentially lower, with topline growth disappointing and continuing to slow. Despite continued deceleration, Mag-7 earnings growth was better than expectations, while ex Mag-7 growth remained weak. At the sector level, earnings growth was weakest and negative for materials, energy and industrials while health care, communication services and utilities posted double-digit EPS growth. Earnings beat rates (reported above estimated) for the S&P 500 remained above the historical average, with growth, defensive and the financials sectors showing beat rates greater than 80%. Earnings revisions (outlook), which have historically been correlated with manufacturing PMIs, firmed in Q4 with analyst earnings increased outnumbering cuts overall and in 6 of 11 sectors, with particular strength in financials and communication services.

Shifting to the market impact, market breadth narrowed significantly again during the quarter, particularly in December, with the S&P equal-weighted index underperforming the cap-weighted index by close to 4% and the Bloomberg Mag 7 Index by almost 13%. From a style and size perspective, large caps mostly outperformed small and midcaps while growth outperformed value across market cap tiers.

Sector leadership narrowed in Q4 and was dominated by financials and cyclical growth stocks. Consumer discretionary was the best performing sector with autos, led by Tesla, and the retail segment prominent drivers. Communication services also outperformed by a



wide margin, driven by strength in media and entertainment stocks, including Alphabet, which more than offset weakness in the telecom segment. The financials and technology sectors also outperformed with the former benefitting from strength in banks and diversified financials and the latter from strong performance by the hardware and semiconductor industries. The materials sector was the biggest laggard in Q4 with significant weakness across all sub-industries. Defensive sectors also continued to underperform with healthcare and utilities particularly weak while the staples sector, which lagged by a smaller margin, was negatively impacted by weakness in household products, food, beverage and tobacco stocks which overwhelmed outperformance by defensive retailers such as Walmart. The more cyclical industrials and energy sectors also underperformed with the later held back by significant weakness in transportation stocks.

Factor performance (long-short/equal weighted/sector neutral) broadened throughout Q4, with momentum a prominent theme. Stocks with positive earnings and sales revisions as well as those with strong price momentum outperformed by a wide margin. Higher volatility growth stocks also outperformed by a sizeable margin, as did those reporting positive earnings surprises. Stocks with strong profitability attributes and/or those making capex investments outperformed to a lesser extent. Stocks with attractive valuations, including higher dividend yields, lagged significantly, as did those buying back shares.

Portfolio performance review

The portfolio underperformed the Russell 2000[®] Index in the fourth quarter. The overall quantitative input underperformed during the quarter, with sentiment, quality and valuation factors hurting relative performance.

At the sector level, stock selection within information technology, industrials, energy and materials detracted from relative performance. Conversely, stock selection within consumer discretionary and health care contributed to returns.

Outlook

As we start the new year, there is an abundance of optimism that the current trends of AI leadership and US exceptionalism will persist. Our base case remains constructive with expectations that the economic recovery will be sustained and broaden supported by easier monetary policy, deregulation in the US and more fiscal stimulus in China.



More specifically, on the policy front most central banks are easing policy although stubborn inflation and resilient economies may limit or slow the pace of rate cuts. Global leading indicators remain bifurcated and choppy however there does appear to be some stabilization in the manufacturing PMIs, although they continue to signal contraction in many of developed economies. Based on history, the current rate-cut cycle should be a tailwind for leading indicators as progress through 2025. While PMIs have done a poor job in recent years of predicting the economy, they continue to be reliable indicators for corroborating the breadth of earnings revisions which also appear to be inflecting higher, in most markets, albeit from depressed levels. Other economic indicators point to a mixed outlook with the OECD CLI hovering above 100 signaling expansion with a strong breadth of economies reporting positive month-month and year-year improvement.

Prominent risks to the consensus outlook, and to a lesser extent ours, include stretched valuations and extremely concentrated markets which could reverse if the AI trade unwinds. A catalyst for such a reversal could be the current gap between the earnings guidance from NVIDIA, and other semiconductor companies, with what hyperscalers are planning to spend. Other risks to monitor include a resurgence of inflation, which could halt the easing cycle, the return of the bond vigilantes in response to debts/deficits, increasing trade tensions and potential tariffs weighing on growth and finally elevated and evolving geopolitical risks.

For your Blended Research strategy, we continue to be encouraged by the relatively broad factor leadership despite the near-record level of concentration in the S&P 500 and Russell 1000[®] Growth indexes. As we have communicated in the past, the most challenging market environment for our approach is one in which a single factor/style or a limited group of stocks dominates performance as was evident in 2020. With the OECD Global & US Composite Leading Indicators (CLI), signaling expansion, our analysis of factor performance through the economic cycle aligns with the outperformance of higher beta stocks with strong earnings and price momentum. While the magnitude is smaller, stocks with attractive valuations have also historically continued to outperform as the economy shifts to the expansion phase of the cycle. Late cycle factors such as profitability and growth as well as the quality-focused fundamental research input to our process tend to be weaker in the front half of the business cycle.

The commentary included in this report was based on a representative fully discretionary portfolio for this product style; as such the commentary may include securities not held in your portfolio due to account, fund, or other limits.



Cash & Cash Equivalents1.1Cand & Cash Equivalents1.1Communication Services3.2Cargurus Inc1.0Yelp Inc0.6EverQuote Inc0.4Lumen Technologies Inc0.4Playtika Holding Corp0.3ZipRecruiter Inc0.3Vimeo Inc0.1Consumer Discretionary11.2Grand Canyon Education Inc1.5Funko Inc1.5PVH Corp1.3Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3WK Kellogg Co0.1Herbalife Ltd0.1	As of 31-Dec-24	Equivalent exposure (%)
Communication Services 3.2 Cargurus Inc 1.0 Yelp Inc 0.6 EverQuote Inc 0.6 Lumen Technologies Inc 0.4 Playtika Holding Corp 0.3 ZipRecruiter Inc 0.3 Vimeo Inc 0.1 Consumer Discretionary 11.2 Grand Canyon Education Inc 1.5 Funko Inc 1.5 PVH Corp 1.3 Sabre Corp 0.9 Mohawk Industries Inc 0.8 Rush Street Interactive Inc 0.8 Bath & Body Works Inc 0.7 International Game Technology PLC 0.7 Wolverine World Wide Inc 0.6 Visteon Corp 0.5 Patrick Industries Inc 0.2 A-Mark Precious Metals Inc 0.2 Genesco Inc 0.1 European Wax Center Inc 0.1 Fox Factory Holding Corp 0.1 Grange Good Foods Co 0.3 Wirk Kellogg Co 0.3	Cash & Cash Equivalents	1.1
Cargurus Inc 1.0 Yelp Inc 0.6 EverQuote Inc 0.6 Lumen Technologies Inc 0.4 Playtika Holding Corp 0.3 ZipRecruiter Inc 0.3 Vimeo Inc 0.1 Consumer Discretionary 11.2 Grand Canyon Education Inc 1.5 Funko Inc 1.5 PVH Corp 1.3 Sabre Corp 0.9 Mohawk Industries Inc 0.8 Rush Street Interactive Inc 0.8 Bath & Body Works Inc 0.7 International Game Technology PLC 0.7 Wolverine World Wide Inc 0.6 Visteon Corp 0.5 Patrick Industries Inc 0.2 A-Mark Precious Metals Inc 0.2 Genesco Inc 0.1 European Wax Center Inc 0.1 Fox Factory Holding Corp 0.1 Consumer Staples 1.6 elf Beauty Inc 0.7 Simply Good Foods Co 0.3 WK Kellogg Co 0.1	•	
Yelp Inc 0.6 EverQuote Inc 0.6 Lumen Technologies Inc 0.4 Playtika Holding Corp 0.3 ZipRecruiter Inc 0.3 Vimeo Inc 0.1 Consumer Discretionary 11.2 Grand Canyon Education Inc 1.5 Funko Inc 1.5 PVH Corp 1.3 Sabre Corp 0.9 Mohawk Industries Inc 0.8 Rush Street Interactive Inc 0.8 Bath & Body Works Inc 0.7 International Game Technology PLC 0.7 Wolverine World Wide Inc 0.2 A-Mark Precious Metals Inc 0.2 Genesco Inc 0.1 European Wax Center Inc 0.1 Fox Factory Holding Corp 0.1 Consumer Staples 1.6 elf Beauty Inc 0.7 Simply Good Foods Co 0.3 WK Kellogg Co 0.1		
EverQuote Inc 0.6 Lumen Technologies Inc 0.4 Playtika Holding Corp 0.3 ZipRecruiter Inc 0.3 Vimeo Inc 0.1 Consumer Discretionary 11.2 Grand Canyon Education Inc 1.5 Funko Inc 1.5 Newell Brands Inc 1.5 PVH Corp 1.3 Sabre Corp 0.9 Mohawk Industries Inc 0.8 Rush Street Interactive Inc 0.8 Bath & Body Works Inc 0.7 International Game Technology PLC 0.7 Wolverine World Wide Inc 0.6 Visteon Corp 0.5 Patrick Industries Inc 0.2 A-Mark Precious Metals Inc 0.2 Genesco Inc 0.1 European Wax Center Inc 0.1 Fox Factory Holding Corp 0.1 Consumer Staples 1.6 elf Beauty Inc 0.7 Simply Good Foods Co 0.3 WK Kellogg Co 0.1	Cargurus Inc	
Lumen Technologies Inc0.4Playtika Holding Corp0.3ZipRecruiter Inc0.3Vimeo Inc0.1Consumer Discretionary11.2Grand Canyon Education Inc1.5Funko Inc1.5Newell Brands Inc1.5PVH Corp1.3Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3WK Kellogg Co0.1	Yelp Inc	0.6
Playtika Holding Corp0.3ZipRecruiter Inc0.3Vimeo Inc0.1Consumer Discretionary11.2Grand Canyon Education Inc1.5Funko Inc1.5Newell Brands Inc1.5PVH Corp1.3Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	EverQuote Inc	0.6
Instruction of the product of the p	Lumen Technologies Inc	0.4
Vimeo Inc 0.1 Consumer Discretionary 11.2 Grand Canyon Education Inc 1.5 Funko Inc 1.5 Funko Inc 1.5 Newell Brands Inc 1.5 PVH Corp 1.3 Sabre Corp 0.9 Mohawk Industries Inc 0.8 Rush Street Interactive Inc 0.8 Bath & Body Works Inc 0.7 International Game Technology PLC 0.7 Wolverine World Wide Inc 0.6 Visteon Corp 0.5 Patrick Industries Inc 0.2 A-Mark Precious Metals Inc 0.2 Genesco Inc 0.1 European Wax Center Inc 0.1 Fox Factory Holding Corp 0.1 Consumer Staples 1.6 elf Beauty Inc 0.7 Simply Good Foods Co 0.3 WK Kellogg Co 0.1	Playtika Holding Corp	0.3
Consumer Discretionary11.2Grand Canyon Education Inc1.5Funko Inc1.5Funko Inc1.5Newell Brands Inc1.5PVH Corp1.3Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.3Wt Kellogg Co0.1	ZipRecruiter Inc	0.3
Grand Canyon Education Inc 1.5 Funko Inc 1.5 Funko Inc 1.5 Newell Brands Inc 1.5 PVH Corp 1.3 Sabre Corp 0.9 Mohawk Industries Inc 0.8 Rush Street Interactive Inc 0.8 Bath & Body Works Inc 0.7 International Game Technology PLC 0.7 Wolverine World Wide Inc 0.6 Visteon Corp 0.5 Patrick Industries Inc 0.2 A-Mark Precious Metals Inc 0.2 Genesco Inc 0.1 European Wax Center Inc 0.1 Fox Factory Holding Corp 0.1 Consumer Staples 1.6 elf Beauty Inc 0.7 Simply Good Foods Co 0.3 Turning Point Brands Inc 0.3 WK Kellogg Co 0.1	Vimeo Inc	0.1
Funko lnc1.5Funko lnc1.5Newell Brands Inc1.3PVH Corp1.3Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Consumer Discretionary	11.2
Newell Brands Inc1.5PVH Corp1.3Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.3WK Kellogg Co0.1	Grand Canyon Education Inc	1.5
PVH Corp1.3Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.3Simply Good Foods Co0.3WK Kellogg Co0.1	Funko Inc	1.5
Sabre Corp0.9Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.3Simply Good Foods Co0.3WK Kellogg Co0.1	Newell Brands Inc	1.5
Mohawk Industries Inc0.8Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	PVH Corp	1.3
Rush Street Interactive Inc0.8Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Sabre Corp	0.9
Bath & Body Works Inc0.7International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Mohawk Industries Inc	0.8
International Game Technology PLC0.7Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Rush Street Interactive Inc	0.8
Wolverine World Wide Inc0.6Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Bath & Body Works Inc	0.7
Visteon Corp0.5Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	International Game Technology PLC	0.7
Patrick Industries Inc0.2A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Wolverine World Wide Inc	0.6
A-Mark Precious Metals Inc0.2Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Visteon Corp	0.5
Genesco Inc0.1European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Patrick Industries Inc	0.2
European Wax Center Inc0.1Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	A-Mark Precious Metals Inc	0.2
Fox Factory Holding Corp0.1Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Genesco Inc	0.1
Consumer Staples1.6elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	European Wax Center Inc	0.1
elf Beauty Inc0.7Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Fox Factory Holding Corp	0.1
Simply Good Foods Co0.3Turning Point Brands Inc0.3WK Kellogg Co0.1	Consumer Staples	1.6
Turning Point Brands Inc0.3WK Kellogg Co0.1	elf Beauty Inc	0.7
WK Kellogg Co 0.1	Simply Good Foods Co	0.3
	Turning Point Brands Inc	0.3
Herbalife Ltd 0.1	WK Kellogg Co	0.1
	Herbalife Ltd	0.1

As of 31-Dec-24	Equivalent
A3 01 31-Dec-24	exposure (%)
Consumer Staples	1.6
USANA Health Sciences Inc	0.0
Dole PLC	0.0
Andersons Inc	0.0
Energy	5.2
Weatherford International PLC	0.9
Permian Resources Corp	0.8
NOV Inc	0.7
World Kinect Corp	0.5
SM Energy Co	0.5
Teekay Tankers Ltd	0.4
Select Water Solutions Inc	0.4
Berry Corp	0.4
Expro Group Holdings NV	0.3
Scorpio Tankers Inc	0.3
Financials	19.7
Columbia Banking System Inc	1.4
Cathay General Bancorp	1.4
Kemper Corp	1.3
Popular Inc	1.3
Wintrust Financial Corp	1.3
Hanover Insurance Group Inc	1.3
SLM Corp	1.3
Voya Financial Inc	1.2
Texas Capital Bancshares Inc	1.1
East West Bancorp Inc	1.1
Jackson Financial Inc	0.9
Lincoln National Corp	0.8
United Community Banks Inc/GA	0.8
Amalgamated Financial Corp	0.7
PROG Holdings Inc	0.7
Bank of NT Butterfield & Son Ltd	0.6
Bank OZK	0.5



Financials19.7Alliance Data Systems Corp0.4Navient Corp0.4Metropolitan Bank Holding Corp0.3Peapack-Gladstone Financial Corp0.3Flushing Financial Corp0.3Hamilton Lane Inc0.1Orrstown Financial Services Inc0.1Kearny Financial Corp/MD0.1Health Care16.6Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.5Phibro Animal Health Corp0.5Pit Drapagutics Inc0.5QuidelOrtho Corp0.4QuidelOrtho Corp0.4Cytokinetics Inc0.4Mitdex Group Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Ornentra Group Holdings Parent Inc0.3Concentra Group Holdings Parent Inc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3Nurix Therapeutics Inc0.3Owens & Minor Inc0.3Owens & Minor Inc0.3Nurix Therapeutics Inc0.3Nurix Therapeutics Inc0.3Owens & Minor Inc0.3Owens & Minor Inc0.3Nurix Therapeutics Inc0.3Owens & Minor Inc0.3Owens & Minor Inc0.3Owens & Minor Inc0.3Owens & Minor Inc0.3Owen	As of 31-Dec-24	Equivalent exposure (%)
Navient Corp0.4Metropolitan Bank Holding Corp0.4Peapack-Gladstone Financial Corp0.3Flushing Financial Corp0.3Hamilton Lane Inc0.1Orrstown Financial Services Inc0.1Kearny Financial Corp/MD0.1Health Care16.6Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.5Health Catalyst Inc0.5Pribro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4MiMedx Group Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Ons0.3Exelixis Inc0.3Stexis Inc0.3Oncentra Group Holdings Parent Inc0.3Exelixis Inc0.3Owens & Minor Inc0.3Minavai LifeSciences Holdings Inc0.3Maravai LifeSciences Holdings Inc0.3	Financials	19.7
Native Crep0.4Metropolitan Bank Holding Corp0.3Peapack-Gladstone Financial Corp0.3Flushing Financial Corp0.1Orrstown Financial Services Inc0.1Kearny Financial Corp/MD0.1Health Care16.6Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5Ordidoc Ventor Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Stexis Inc0.3Mineal Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3Maravai LifeSciences Holdings Inc0.3	Alliance Data Systems Corp	
Peapack-Gladstone Financial Corp0.3Flushing Financial Corp0.3Hamilton Lane Inc0.1Orrstown Financial Services Inc0.1Kearny Financial Corp/MD0.1Health Care16.6Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Phibro Animal Health Corp0.5Pibro Animal Health Corp0.5Organot Co0.4Zimvie Inc0.5Pibro Animal Health Corp0.5Pic Therapeutics Inc0.4Cytokinetics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Stealt Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals Inc0.3Mised Socience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3		
Flushing Financial Corp0.3Hamilton Lane Inc0.1Orrstown Financial Services Inc0.1Kearny Financial Corp/MD0.1Health Care16.6Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Phibro Animal Health Corp0.5Phibro Animal Health Corp0.5Organon & Co0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Earl Therapeutics Inc0.3Outent Group Holdings Parent Inc0.3Exelixis Inc0.3Exelixis Inc0.3Owens & Minor Inc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Metropolitan Bank Holding Corp	0.4
Hamilton Lane Inc 0.1 Orrstown Financial Services Inc 0.1 Kearny Financial Corp/MD 0.1 Health Care 16.6 Prestige Brands Holdings Inc 1.7 Encompass Health Corp 1.6 Organon & Co 1.1 Teladoc Health Inc 0.6 Natera Inc 0.6 Zimvie Inc 0.5 Health Catalyst Inc 0.5 Phibro Animal Health Corp 0.5 Phibro Animal Health Corp 0.5 QuidelOrtho Corp 0.4 Cytokinetics Inc 0.4 Cytokinetics Inc 0.4 Concentra Group Holdings Parent Inc 0.3 Exelixis Inc 0.3 Beam Therapeutics Inc 0.3 Amneal Pharmaceuticals Inc 0.3 Kiniksa Pharmaceuticals Inc 0.3 Ovens & Minor Inc 0.3 Owens & Minor Inc 0.3	Peapack-Gladstone Financial Corp	0.3
Orrstown Financial Services Inc 0.1 Kearny Financial Corp/MD 0.1 Health Care 16.6 Prestige Brands Holdings Inc 1.7 Encompass Health Corp 1.6 Organon & Co 1.1 Teladoc Health Inc 0.6 Natera Inc 0.6 Zimvie Inc 0.5 Health Catalyst Inc 0.5 Phibro Animal Health Corp 0.5 Prict Therapeutics Inc 0.5 QuidelOrtho Corp 0.4 Cytokinetics Inc 0.4 Concentra Group Holdings Parent Inc 0.3 Exelixis Inc 0.3 Mimeal Pharmaceuticals Inc 0.3 Kymera Therapeutics Inc 0.3 Stelixis Inc 0.3 Beam Therapeutics Inc 0.3 Amneal Pharmaceuticals Inc 0.3 Kiniksa Pharmaceuticals International Plc 0.3 Overns & Minor Inc 0.3 Maravai LifeSciences Holdings Inc 0.3	Flushing Financial Corp	0.3
Kearny Financial Corp/MD0.1Health Care16.6Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Concentra Group Holdings Parent Inc0.3Kiniksa Pharmaceuticals Inc0.3Concentra Group Holdings Parent Inc0.3Concentra Group Holdings Parent Inc0.3Concentra Group Holdings Parent Inc0.3Mineal Pharmaceuticals Inc0.3Amneal Pharmaceuticals Inc0.3Mixes Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Ovens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Hamilton Lane Inc	0.1
Health Care16.6Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Mineal Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals Inc0.3Maravai LifeSciences Holdings Inc0.3Maravai LifeSciences Holdings Inc0.3	Orrstown Financial Services Inc	0.1
Prestige Brands Holdings Inc1.7Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.3Exelixis Inc0.3Exelixis Inc0.3Stexilixis Inc0.3Oxocentra Group Holdings Parent Inc0.3Stexilixis Inc0.3Mineal Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals International Plc0.3Ovens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3		0.1
Encompass Health Corp1.6Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5Pric Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Seam Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Seam Therapeutics Inc0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Health Care	16.6
Organon & Co1.1Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Catalyst Pharmaceuticals Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3O.30.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Prestige Brands Holdings Inc	1.7
Teladoc Health Inc0.6Natera Inc0.6Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Xinksa Pharmaceuticals Inc0.3Concentra Group Holdings Parent Inc0.3Concentra Group Holdings Parent Inc0.3Kiniksa Pharmaceuticals Inc0.3Amneal Pharmaceuticals Inc0.3Mineal Pharmaceuticals Inc0.3Amneal Pharmaceuticals Inc0.3Mineal Pharmaceuticals Inc0.3Mineal Pharmaceuticals Inc0.3Mineal Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Encompass Health Corp	1.6
Natera Inc0.6Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4Cytokinetics Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Mimeal Pharmaceuticals Inc0.3Amneal Pharmaceuticals Inc0.3Amneal Pharmaceuticals Inc0.3Mines Ammaceuticals Inc0.3Mines Pharmaceuticals Inc0.3Mines Pharmaceuticals Inc0.3Mines Pharmaceuticals Inc0.3Mines Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Organon & Co	1.1
Autor Inc0.5Zimvie Inc0.5Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4MiMedx Group Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Teladoc Health Inc	0.6
Health Catalyst Inc0.5Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4MiMedx Group Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Natera Inc	0.6
Phibro Animal Health Corp0.5PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4MiMedx Group Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Therapeutics Inc0.3Stelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Zimvie Inc	0.5
PTC Therapeutics Inc0.5QuidelOrtho Corp0.4Cytokinetics Inc0.4MiMedx Group Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Health Catalyst Inc	0.5
QuidelOrtho Corp0.4Cytokinetics Inc0.4MiMedx Group Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Phibro Animal Health Corp	0.5
Cytokinetics Inc0.4MiMedx Group Inc0.4Catalyst Pharmaceuticals Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.3Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	PTC Therapeutics Inc	0.5
MiMedx Group Inc0.4Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	QuidelOrtho Corp	0.4
Catalyst Pharmaceuticals Inc0.4Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Cytokinetics Inc	0.4
Kymera Therapeutics Inc0.4Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	MiMedx Group Inc	0.4
Concentra Group Holdings Parent Inc0.3Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Catalyst Pharmaceuticals Inc	0.4
Exelixis Inc0.3Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Kymera Therapeutics Inc	0.4
Beam Therapeutics Inc0.3Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Concentra Group Holdings Parent Inc	0.3
Amneal Pharmaceuticals Inc0.3Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Exelixis Inc	0.3
Twist Bioscience Corp0.3Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Beam Therapeutics Inc	0.3
Kiniksa Pharmaceuticals International Plc0.3Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Amneal Pharmaceuticals Inc	0.3
Owens & Minor Inc0.3Maravai LifeSciences Holdings Inc0.3	Twist Bioscience Corp	0.3
Maravai LifeSciences Holdings Inc 0.3	Kiniksa Pharmaceuticals International Plc	0.3
	Owens & Minor Inc	0.3
	Maravai LifeSciences Holdings Inc	0.3
		0.3

As of 31-Dec-24	Equivalent
	exposure (%)
Health Care	16.6
Protagonist Therapeutics Inc	0.3
Alkermes Plc	0.3
UFP Technologies Inc	0.3
Arcus Biosciences Inc	0.3
Entrada Therapeutics Inc	0.3
Amicus Therapeutics Inc	0.3
BioLife Solutions Inc	0.3
Neurocrine Biosciences Inc	0.3
ACADIA Pharmaceuticals Inc	0.3
Voyager Therapeutics Inc	0.3
Arcturus Therapeutics Holdings Inc	0.2
Ultragenyx Pharmaceutical Inc	0.2
Vanda Pharmaceuticals Inc	0.2
Anika Therapeutics Inc	0.2
Novavax Inc	0.2
Prothena Corp PLC	0.1
Zymeworks Inc	0.1
Veracyte Inc	0.1
Adaptive Biotechnologies Corp	0.0
Collegium Pharmaceutical Inc	0.0
Industrials	16.1
Armstrong World Industries Inc	1.4
API Group Corp	1.4
AZEK Co Inc	1.2
Flowserve Corp	1.2
TaskUS Inc	1.2
TriNet Group Inc	1.1
REV Group Inc	0.9
Saia Inc	0.9
CACI International Inc	0.8
GMS Inc	0.7
WNS Holdings Ltd	0.7



As of 31-Dec-24	Equivalent exposure (%)
Industrials	16.1
BlueLinx Holdings Inc	0.7
Builders FirstSource Inc	0.6
Lyft Inc	0.6
Timken Co	0.6
Tutor Perini Corp	0.5
Dun & Bradstreet Holdings Inc	0.5
Blue Bird Corp	0.3
Standardaero Inc	0.2
JELD-WEN Holding Inc	0.2
Cimpress PLC	0.1
Pitney Bowes Inc	0.1
Innodata Inc	0.1
Quad/Graphics Inc	0.0
Hyster-Yale Inc	0.0
SiteOne Landscape Supply Inc	0.0
Information Technology	13.6
Advanced Energy Industries Inc	1.3
Verint Systems Inc	1.3
PagerDuty Inc	1.1
Elastic NV	1.0
Corsair Gaming Inc	0.8
Clear Secure Inc	0.8
Axcelis Technologies Inc	0.8
Sanmina Corp	0.8
Plexus Corp	0.5
FormFactor Inc	0.5
Photronics Inc	0.5
Nutanix Inc	0.5
Yext Inc	0.4
Methode Electronics Inc	0.4
Cirrus Logic Inc	0.4
Five9 Inc	0.4

As of 31-Dec-24	Equivalent
	exposure (%)
Information Technology	13.6
Onestream Inc	0.4
SentinelOne Inc	0.4
ACI Worldwide Inc	0.4
Kimball Electronics Inc	0.3
ScanSource Inc	0.2
nCino Inc	0.2
ADTRAN Holdings Inc	0.1
Consensus Cloud Solutions Inc	0.1
ServiceTitan Inc	0.1
Unisys Corp	0.1
Alpha & Omega Semiconductor Ltd	0.0
Materials	4.9
Element Solutions Inc	1.4
Avient Corp	1.0
Rayonier Advanced Materials Inc	0.6
Tronox Holdings PLC	0.6
Radius Recycling Inc	0.5
Perimeter Solutions Inc	0.3
Olympic Steel Inc	0.3
Ryerson Holding Corp	0.3
Mativ Holdings Inc	0.0
Real Estate	5.2
Piedmont Office Realty Trust Inc REIT	1.5
Highwoods Properties Inc REIT	1.3
Cushman & Wakefield PLC	1.0
Broadstone Net Lease Inc REIT	1.0
Essential Properties Realty Trust Inc REIT	0.3
Uniti Group Inc REIT	0.0
Innovative Industrial Properties Inc REIT	0.0
Utilities	1.5
UGI Corp	0.6
Portland General Electric Co	0.5

As of 31-Dec-24	Equivalent exposure (%)
Utilities	1.5
National Fuel Gas Co	0.4
Southwest Gas Holdings Inc	0.1

The Global Industry Classification Standard (GICS[®]) was developed by and/or is the exclusive property of MSCI, Inc. and S&P Global Market Intelligence Inc. ("S&P Global Market Intelligence"). GICS is a service mark of MSCI and S&P Global Market Intelligence and has been licensed for use by MFS. MFS has applied its own internal sector/industry classification methodology for equity securities and non-equity securities that are unclassified by GICS.



Additional Disclosures



Frank Russell Company ("Russell") is the source and owner of the Russell Index data contained or reflected in this material and all trademarks, service marks and copyrights related to the Russell Indexes. Russell[®] is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell's express written consent. Russell does not promote, sponsor or endorse the content of this communication.

The views expressed in this [report, presentation, speech, etc.] are those of MFS, and are subject to change at any time. These views should not be relied upon as investment advice, as securities recommendations, or as an indication of trading intent on behalf of any MFS investment product.